GoodRx Holdings, Inc. (NASDAQ:GDRX) Sees Large Drop in Short Interest

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 7,470,000 shares, a drop of 5.8% from the December 15th total of 7,930,000 shares. Approximately 8.6% of the company’s shares are sold short. Based on an average daily trading volume, of 1,370,000 shares, the days-to-cover ratio is currently 5.5 days.

Institutional Investors Weigh In On GoodRx

Large investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in shares of GoodRx during the third quarter valued at approximately $33,000. Fortem Financial Group LLC increased its stake in GoodRx by 7.2% during the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after purchasing an additional 7,996 shares in the last quarter. XTX Topco Ltd raised its holdings in GoodRx by 42.4% during the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after buying an additional 8,801 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in GoodRx by 5.9% during the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after buying an additional 9,200 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new position in shares of GoodRx in the third quarter valued at $73,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GDRX. Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. KeyCorp cut their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Morgan Stanley reduced their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Citigroup lowered their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, Barclays reduced their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Trading Up 3.4 %

Shares of GDRX stock opened at $4.57 on Friday. The firm has a 50 day moving average of $4.59 and a 200-day moving average of $6.45. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.